WO2026012479 - SELECTIVE CDK2 INHIBITOR AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/012479
Publication Date
15.01.2026
International Application No.
PCT/CN2025/108192
International Filing Date
11.07.2025
Title **
[English]
SELECTIVE CDK2 INHIBITOR AND USE THEREOF
[French]
INHIBITEUR SÉLECTIF DE CDK2 ET SON UTILISATION
[Chinese]
选择性CDK2抑制剂及其应用
Applicants **
SHANGHAI SIMCERE ZAIMING BIOTECHNOLOGY CO., LTD.
Inventors
MAI, Wansun
LIU, Xiaowu
HUAN, Xiang
DENG, Zhixiong
XU, Mengmeng
ZHU, Wei
LI, Zhengtao
Priority Data
202410937134.X
12.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1923 | |
| EPO | Filing, Examination, Granting | 15430 | |
| Japan | Filing, Examination, Granting | 2424 | |
| South Korea | Filing, Examination, Granting | 2550 | |
| USA | Filing, Examination, Granting | 5140 |
Total:
27,467
Contact Us
Abstract[English]
The present invention relates to a cyclin-dependent kinase (CDK)-targeting compound, and specifically provides a compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compound has the substituents and structural features recited in the present application. The present application further recites a pharmaceutical composition comprising the compound of formula (I) or the stereoisomer thereof or the pharmaceutically acceptable salt thereof, and a pharmaceutical use of the compound or the stereoisomer thereof or the pharmaceutically acceptable salt thereof.[French]
La présente invention concerne un composé ciblant la kinase cycline-dépendante (CDK), et concerne spécifiquement un composé de formule (I) ou un stéréoisomère de celui-ci ou un sel pharmaceutiquement acceptable de celui-ci. Le composé possède les substituants et les caractéristiques structurales tels que définis dans la présente demande. La présente invention concerne en outre une composition pharmaceutique comprenant le composé de formule (I) ou son stéréoisomère ou son sel pharmaceutiquement acceptable, ainsi qu'une utilisation pharmaceutique du composé ou du stéréoisomère de celui-ci ou du sel pharmaceutiquement acceptable de celui-ci.[Chinese]
本发明内容涉及靶向细胞周期蛋白激酶(CDK)的化合物，具体提供了式(I)的化合物或其立体异构体或其药学上可接受的盐，所述化合物具有本申请所述取代基和结构特征。本申请还描述了包含式(I)化合物或其立体异构体或其药学上可接受的盐的药物组合物，以及所述化合物或其立体异构体或其药学上可接受的盐在医药上的应用。